About XOMA Corporation
XOMA Corporation is a company based in Berkeley (United States) founded in 1981 was acquired by Ligand Pharmaceuticals in July 2026. The company has 13 employees as of December 31, 2024. XOMA Corporation has completed 6 acquisitions, including Generation Bio, Kinnate Biopharma and Lava Therapeutics. XOMA Corporation offers products and services including Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody. XOMA Corporation operates in a competitive market with competitors including Neurocrine, argenx, Crinetics, MacroGenics and Alexion, among others.
- Headquarter Berkeley, United States
- Employees 13 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Xoma Royalty Corporation
-
Annual Revenue
$28.49 M (USD)498.72as on Dec 31, 2024
-
Net Profit
-$13.82 M (USD)66.15as on Dec 31, 2024
-
EBITDA
-$39.76 M (USD)-89.44as on Dec 31, 2024
-
Latest Funding Round
$1.9 M (USD), Post-IPO
Oct 14, 2020
-
Investors
SVB
& 2 more
-
Employee Count
13
as on Dec 31, 2024
-
Investments & Acquisitions
Generation Bio
& 5 more
-
Acquired by
Ligand Pharmaceuticals
(Jul 14, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of XOMA Corporation
XOMA Corporation is a publicly listed company on the NASDAQ with ticker symbol XOMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of XOMA Corporation
XOMA Corporation offers a comprehensive portfolio of products and services, including Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody.
Service for acquiring rights to biotech royalties and milestones.
Platform offering phage display technology for drug development.
Therapeutic asset for potential royalty and milestone payments.
Antibody asset available for licensing in drug candidates.
People of XOMA Corporation
Unlock access to complete
Unlock access to complete
Funding Insights of XOMA Corporation
Investors in XOMA Corporation
XOMA Corporation has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include SVB, Rezolute and Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
Locked | Locked | Locked | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Locked | Locked | Locked | |
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Locked | Locked | Locked |
Investor details for XOMA Corporation
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by XOMA Corporation
XOMA Corporation has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Generation Bio, Kinnate Biopharma and Lava Therapeutics.
Investment portfolio details for XOMA Corporation
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cytokine-based immunotherapies for cancer treatment are developed.
|
Locked | Locked | 2023 | Locked | |
|
Small molecule therapeutics for cancer treatment are developed.
|
Locked | Locked | 2018 | Locked | |
|
Gene therapies for rare liver and eye diseases are developed.
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for XOMA Corporation
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - XOMA Corporation
Detailed financials for XOMA Corporation
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xoma Corporation Comparisons
Peer comparison for XOMA Corporation
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of XOMA Corporation
XOMA Corporation operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, argenx, Crinetics, MacroGenics and Alexion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| Locked | Locked | Locked |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| Locked | Locked | Locked |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
Detailed competitors of XOMA Corporation
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xoma Corporation
Complete news archive for XOMA Corporation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about XOMA Corporation
XOMA Corporation was founded in 1981 and raised its 1st funding round 37 years after it was founded.
XOMA Corporation is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
As of Dec 31, 2024, the latest employee count at XOMA Corporation is 13.
Annual revenue of XOMA Corporation is $28.49M as on Dec 31, 2024.
XOMA Corporation was founded in 1981 and is headquartered in Berkeley, United States. Operations focus on biotechnology, with antibody-based therapeutics developed for endocrine and metabolic disorders. The pipeline features XOMA-358, a drug candidate in Phase 2 trials for congenital hyperinsulinism and post-bariatric surgery hyperinsulinism. Development efforts target unmet needs in these therapeutic areas through innovative antibody engineering.
XOMA Corporation's top competitors include argenx, Crinetics and Neurocrine.
XOMA Corporation offers Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody.
Yes, XOMA Corporation is publicly traded on NASDAQ under the ticker symbol XOMA.
XOMA Corporation has made 6 acquisitions, including Generation Bio, Kinnate Biopharma, and Lava Therapeutics.
XOMA Corporation has 3 investors. Key investors include SVB, Rezolute, and Ligand Pharmaceuticals.
The ticker symbol of XOMA Corporation is XOMA on NASDAQ.